sales@angenesci.com
Login | Register
logo
Structures Search
Home Aminos N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

CAS No.:
1056634-68-4
Catalog Number:
AG00388S
Molecular Formula:
C23H22N6O2
Molecular Weight:
414.4598
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
95%
In Stock USA
United States
$136
- +
10mg
95%
In Stock USA
United States
$169
- +
50mg
95%
In Stock USA
United States
$436
- +
100mg
95%
In Stock USA
United States
$753
- +
200mg
95%
In Stock USA
United States
$1019
- +
Product Description
Catalog Number:
AG00388S
Chemical Name:
N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
CAS Number:
1056634-68-4
Molecular Formula:
C23H22N6O2
Molecular Weight:
414.4598
MDL Number:
MFCD16038899
IUPAC Name:
N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
InChI:
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
InChI Key:
ZVHNDZWQTBEVRY-UHFFFAOYSA-N
SMILES:
N#CCNC(=O)c1ccc(cc1)c1ccnc(n1)Nc1ccc(cc1)N1CCOCC1
UNII:
6O01GMS00P
Properties
Complexity:
615  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
414.18g/mol
Formal Charge:
0
Heavy Atom Count:
31  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
414.469g/mol
Monoisotopic Mass:
414.18g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
103A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.6  
Literature
Title Journal
Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood cancer journal 20180301
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. The Lancet. Haematology 20180201
The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20160801
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Molecular diagnosis & therapy 20121001
Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501
Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501
JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 20120401
New generation small-molecule inhibitors in myeloproliferative neoplasms. Current opinion in hematology 20120301
Incyte comes of age with JAK inhibitor approval. Nature biotechnology 20120109
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 20111201
Targeting myeloproliferative neoplasms with JAK inhibitors. Current opinion in hematology 20110301
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 20100624
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic & medicinal chemistry letters 20091015
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 20090801
Properties